Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 in Leigh Syndrome
Key Insights
The FDA has granted Rare Pediatric Disease designation to Thiogenesis Therapeutics (search)' lead candidate TTI-0102 for the treatment of Leigh syndrome (search), a serious mitochondrial disorder affecting children.
The designation provides Thiogenesis with the potential to receive a Priority Review Voucher upon NDA approval, representing a valuable strategic asset for the company.
Thiogenesis has strengthened its Phase 2 protocol with pharmacokinetic learnings from its MELAS (search) clinical program and is completing final study start-up activities.
Thiogenesis Therapeutics (search), Corp., a San Diego-based clinical-stage biotechnology company, announced on July 13, 2026 that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome (search). The designation marks a significant regulatory milestone for the company's Leigh syndrome spectrum program and underscores the urgent need for effective therapies in this devastating pediatric mitochondrial disorder.
The FDA's Rare Pediatric Disease designation is reserved for therapies intended to treat serious or life-threatening diseases that primarily affect children from birth through 18 years of age. Upon approval of a future New Drug Application, the designation entitles Thiogenesis to receive a Priority Review Voucher, which can be redeemed to obtain priority review of another marketing application or sold to another sponsor. Historically, such vouchers have represented valuable strategic assets for biotechnology companies.
"Receiving Rare Pediatric Disease designation is an important regulatory milestone for our Leigh syndrome (search) spectrum program and further expands Thiogenesis' regulatory portfolio," said Patrice Rioux, M.D., Ph.D., Chief Executive Officer of Thiogenesis. "The designation recognizes the significant unmet medical need in Leigh syndrome and reinforces our confidence in the potential of TTI-0102 to address that need."
Phase 2 Trial Preparation Underway
Thiogenesis is advancing toward the initiation of a Phase 2 clinical trial for TTI-0102 in Leigh syndrome (search). According to Dr. Rioux, the company has strengthened its Phase 2 protocol by incorporating important pharmacokinetic learnings from its MELAS (search) clinical program, another mitochondrial disorder under investigation. The company is now completing final study start-up activities and expects to begin generating clinical data in the near future.
"Since receiving FDA clearance of our IND, we have strengthened our Phase 2 protocol by incorporating important pharmacokinetic learnings from our MELAS (search) clinical program. We are now completing final study start-up activities and look forward to initiating the Phase 2 trial and generating clinical data," Dr. Rioux stated.
TTI-0102: A Differentiated Prodrug Approach
TTI-0102 is a patented new chemical entity designed to deliver sustained cysteamine exposure through proprietary prodrug chemistry rather than conventional controlled-release formulation technology. This differentiated approach is intended to improve tolerability, convenience and therapeutic exposure relative to existing cysteamine therapies.
The company's lead program is in nephropathic cystinosis (search), where TTI-0102 is advancing toward late-stage clinical development. Beyond cystinosis, Thiogenesis is developing TTI-0102 for primary mitochondrial diseases, including Leigh syndrome (search) spectrum, reflecting the broad therapeutic potential of its sulfur-based thiol platform across rare pediatric, metabolic and mitochondrial disorders.